Early Screening of Hepatocellular Carcinoma in Cirrhotic Patients: a Prospective Study

05:05 EST 19th December 2014 | BioPortfolio

Summary

Although serum alpha-fetoprotein level and abdominal sonography are the main methods to screening hepatocellular carcinoma (HCC) in cirrhotic patients, the adequate time and methods used are not completely well-defined. This study aims to assess the better timing and methods for prospectively screening HCC in patients with cirrhosis

Description

Well-diagnosed consecutive patients with cirrhosis were enrolled through a designed questionnaire to obtain basic information about gender, age, etiology of cirrhosis, conventional liver function tests, serum AFP level, education level, substance use including smoking, alcohol drinking, betel quid chewing, history of familial HCC, etc. Then the patients was followed by periodic abdominal sonography examination and determination of AFP and liver function. If AFP elevated or liver nodule appears, effort to diagnose HCC will be performed.If HCC was performed, the survival will be followed-up.

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Conditions

Cirrhosis

Location

Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung
Taiwan
807

Status

Recruiting

Source

Kaohsiung Medical University Chung-Ho Memorial Hospital

Results (where available)

View Results

Links

Clinical Trials [122 Associated Clinical Trials listed on BioPortfolio]

Role of Nitric Oxide in Cirrhosis: Relationship With Systemic Hemodynamics, Renal Function, Vasoactive Systems and Endotoxemia

This study is to determine whether a compound, nitric oxide, made within the body, is the factor responsible for the changes in blood pressure and renal (kidney) functions that may occur d...

Intestinal Barrier Function and Liver Cirrhosis

Patients with liver cirrhosis have an increased risk to develop life-threatening complications such as spontaneous bacterial peritonitis (SBP). Impairment in the intestinal barrier, change...

Phase 1 Study of L-NMMA in Patients With Liver Cirrhosis

Phase 1 study of the effects of nitric oxide inhibition with L-NMMA in patients with liver cirrhosis and healthy controls. It is hypothesized that nitric oxide availability is increased in...

A Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis

Entacavir and tenofovir are two first line therapies for chronic hepatitis B. Both agents have been claimed equivalent in treatment, there are no head to head trials available in the liter...

Effect of Pioglitazone on Portal and Systemic Hemodynamics in Patients With Advanced Cirrhosis

The purpose of this study is to investigate the response to pioglitazone on the hepatic venous pressure gradient and peripheral vascular responsiveness to vasoconstrictors in patients with...

PubMed Articles [526 Associated PubMed Articles listed on BioPortfolio]

Portal vein thrombosis in liver cirrhosis.

Portal vein thrombosis (PVT) is considered to be a frequent complication of liver cirrhosis. However, unlike PVT in patients without cirrhosis, very few data are available on the natural history and m...

The Epidemiology of Cirrhosis in the United States: A Population-based Study.

Liver cirrhosis is an important public health concern in the United States and a significant source of morbidity and mortality. However, the epidemiology of cirrhosis is incompletely understood. The a...

Platelets and fibrin in progression of liver disease: friends or foes?

Patients with chronic liver diseases may acquire substantial alterations in their hemostatic system when the disease progresses to fibrosis or cirrhosis[1]. Paradoxically, patients with cirrhosis show...

Cirrhosis and its complications: Evidence based treatment.

Cirrhosis results from progressive fibrosis and is the final outcome of all chronic liver disease. It is among the ten leading causes of death in United States. Cirrhosis can result in portal hyperten...

Progression from cirrhosis to cancer is associated with early ubiquitin post-translational modifications: identification of new biomarkers of cirrhosis at risk of malignancy.

Cirrhosis is a lesion at risk of hepatocellular carcinoma (HCC). Identifying mechanisms associated with the transition from cirrhosis to HCC and characterizing biomarkers of cirrhosis at high risk of ...

Medical and Biotech [MESH] Definitions

Experimentally induced chronic injuries to the parenchymal cells in the liver to achieve a model for LIVER CIRRHOSIS.

FIBROSIS of the hepatic parenchyma due to obstruction of BILE flow (CHOLESTASIS) in the intrahepatic or extrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC; BILE DUCTS, EXTRAHEPATIC). Primary biliary cirrhosis involves the destruction of small intra-hepatic bile ducts and bile secretion. Secondary biliary cirrhosis is produced by prolonged obstruction of large intrahepatic or extrahepatic bile ducts from a variety of causes.

FIBROSIS of the hepatic parenchyma due to chronic excess ALCOHOL DRINKING.

Abnormal increase of resistance to blood flow within the hepatic PORTAL SYSTEM, frequently seen in LIVER CIRRHOSIS and conditions with obstruction of the PORTAL VEIN.

Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.

More From BioPortfolio on "Early Screening of Hepatocellular Carcinoma in Cirrhotic Patients: a Prospective Study"

Search BioPortfolio:
Loading
Advertisement
Advertisement